Marapharm Ventures Inc. Announces $4,633,348.00 of Warrants Exercised
KELOWNA, British Columbia, Sept. 11, 2017 /PRNewswire/ --
Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM.CN) (FSE: 2M0) 'Marapharm' or the 'Company' announces that $4,633,348.00 has been received from the exercise of warrants. The warrants were issued in a unit offering containing 1 common share and 1 share purchase warrant. The right to exercise the warrants expired on September 6, 2017 at 5 pm PST.
"We are very pleased that our shareholders continue to show confidence in Marapharm as evidenced by the exercise of their warrants. Ongoing working capital, including the $4,633,348.00 from the warrants, is essential to the Marapharm brand as the company builds out cannabis operations in 3 U.S. States. Marapharm facilities will incorporate state of the art security and environmental standards. Compliance elements are of the highest concern and are being built into every operational element," Linda Sampson, Marapharm CEO.
There are no more unit offerings with warrants to be exercised at this time; however, there is a 'warrant only' offering announced August 8, 2017 still outstanding.
About Marapharm Ventures Inc.
Marapharm is a publicly traded company on the Canadian Stock Exchange investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide. www.marapharm.com
Social Media:
Facebook: facebook.com/marapharm
Twitter: twitter.com/marapharm
Stock Exchanges:
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldork, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
Forward - Looking Statements:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
For further information:
Linda Sampson
CEO
Phone: 778-583-4476
E-mail: [email protected]
www.marapharm.com
SOURCE Marapharm Ventures Inc.
Share this article